FrancophonIA/ELRC3.0 huggingface dataset:
English: It is important to tell your doctor or pharmacist if you are taking any of the following: - Medicines containing didanosine (for HIV infection): Taking Atripla with other antiviral medicines that contain didanosine can raise the levels of didanosine in your blood and may reduce CD4 cell counts.
Croatian: - Lijekovi koji sadržavaju didanozin (za liječenje infekcije HIV-om): Uzimanjem Atriple s drugim antivirusnim lijekovima koji sadržavaju didanozin može Vam se povećati razina didanozina u krvi i smanjiti broj CD4 stanica.
English: It is anticipated that tenofovir exposure (AUC) will be approximately 30% lower following administration of Atripla on an empty stomach as compared to the individual component tenofovir disoproxil when taken with food (see section 5.2).
Croatian: Predviđa se izloženost tenofoviru (AUC) približno 30% manja nakon uzimanja Atriple na prazan želudac, u usporedbi s uzimanjem pojedinačne komponente tenofovirdizoproksila s hranom (vidjeti dio 5.2).
English: Monitoring of renal function may be indicated, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
Croatian: Može biti indiciran nadzor funkcije bubrega, osobito u bolesnika s postojećom sistemskom bolešću ili bolešću bubrega te u bolesnika koji uzimaju nefrotoksične lijekove.
English: Headache has been reported in clinical studies with emtricitabine (see section 4.8).
Croatian: U kliničkim ispitivanjima s emtricitabinom prijavljeni su slučajevi glavobolje (vidjeti dio 4.8).
English: Dizziness was also seen in clinical studies with emtricitabine and tenofovir disoproxil.
Croatian: Omaglica je uočena i u kliničkim ispitivanjima s emtricitabinom i tenofovirdizoproksilom.
English: Your doctor may also order blood tests during treatment to monitor your kidneys.
Croatian: Liječnik može zatražiti krvne pretrage i tijekom liječenja u cilju praćenja rada Vaših bubrega.
English: In a study of HIV infected intravenous drug users, co-administration of efavirenz with methadone resulted in decreased plasma levels of methadone and signs of opiate withdrawal.
Croatian: U istraživanju s intravenskim ovisnicima o drogama inficiranima virusom HIV-a istodobna primjena efavirenza i metadona dovela je do smanjenja razine metadona u plazmi i znakova apstinencije od opijata.
English: The pharmacokinetics of emtricitabine have not been studied in non-HBV infected patients with varying degrees of hepatic insufficiency.
Croatian: Farmakokinetika emtricitabina nije ispitana u bolesnika koji nisu zaraženi virusom HBV-a, a koji imaju različiti stupanj hepatalne insuficijencije.
English: Table 1 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, twice daily as “b.i.d.”,
Croatian: Interakcije između Atriple ili njenih pojedinačnih komponenti i drugih lijekova navedene su u nastavku u Tablici 1 (povećanje je označeno kao „↑”, smanjenje kao „↓”, bez promjene kao „↔”, dvaput na dan kao „b.i.d.”, jedanput na dan kao „q.d.” i svakih 8 sati kao „q8h”).
English: Other macrolide antibiotics, such as erythromycin, have not been studied in combination with Atripla.
Croatian: Nisu ispitivane kombinacije drugih makrolidnih antibiotika, npr. eritromicina, i Atriple.
English: - antiarrhythmics of classes IA and III, - neuroleptics, antidepressive agents, - certain antibiotics including some agents of the following classes: macrolides,
Croatian: Ti lijekovi uključuju: - antiaritmike skupina IA i III - neuroleptike, antidepresive - određene antibiotike uključujući neke lijekove iz sljedećih skupina: makrolidi, fluorokinoloni,
English: - if you are taking other medicines that contain efavirenz, emtricitabine, tenofovir disoproxil, tenofovir alafenamide, or lamivudine or adefovir dipivoxil.
Croatian: ako uzimate druge lijekove koji sadržavaju efavirenz, emtricitabin, tenofovirdizoproksil, tenofoviralafenamid kao i lamivudin ili adefovirdipivoksil.
English: No dose adjustment of rifampicin is recommended when given with Atripla.
Croatian: Ne preporučuje se prilagođavanje doze rifamipicina kada se primjenjuje s Atriplom.
English: 30 film-coated tablets 90 (3 bottles of 30) film-coated tablets
Croatian: OBLIK I SADRŽAJ 30 filmom obloženih tableta 90 (3 boce po 30) filmom obloženih tableta
English: If you had a rash while taking another NNRTI, you may be at higher risk of getting a rash with Atripla.
Croatian: Ako ste imali osip tijekom uzimanja drugog NNRTI lijeka, kod Vas postoji veći rizik od pojave osipa tijekom uzimanja Atriple.
English: If concomitant use of Atripla and nephrotoxic agents (e.g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir, interleukin-2) is unavoidable, renal function must be monitored weekly (see section 4.5).
Croatian: Ako se ne može izbjeći istodobna primjena Atriple i nefrotoksičnih lijekova (npr. aminoglikozida, amfotericina B, foskarneta, ganciklovira, pentamidina, vankomicina, cidofovira, interleukina-2), nužno je jednom tjedno provjeravati funkciju bubrega (vidjeti dio 4.5).
English: BOTTLE AND CARTON LABELLING
Croatian: OZNAČIVANJE NA BOCI I KUTIJI
English: • pain, stomach pain
Croatian: • bol, bol u trbuhu
English: • The M184V/I mutation developed in 2/19 (10.5%) isolates analysed from patients in the efavirenz + emtricitabine + tenofovir disoproxil group and in 10/29 (34.5%) isolates analysed from the efavirenz + lamivudine/zidovudine group (p-value < 0.05, Fisher's Exact test comparing the emtricitabine + tenofovir disoproxil group to the lamivudine/zidovudine group among all subjects).
Croatian: • Mutacija M184V/I razvila se u 2/19 (10,5%) izolata analiziranih u bolesnika iz skupine efavirenz + emtricitabin + tenofovirdizoproksil te u 10/29 (34,5%) izolata analiziranih u bolesnika iz skupine efavirenz + lamivudin/zidovudin (p-vrijednost < 0,05, Fisherov egzaktni test koji uspoređuje skupinu emtricitabin
English: One child was reported to have a neural tube defect, and the frequency and pattern of other birth defects were similar to those seen in children exposed to non-efavirenz-containing regimens, as well as those in HIV negative controls.
Croatian: U jednog djeteta je prijavljeno oštećenje neuralne cijevi, dok su učestalost i obrazac pojavljivanja drugih kongenitalnih malformacija bili slični onima opaženim u djece čije su majke bile izložene režimima liječenja bez efavirenza te onima u kontrolnoj skupini HIV-negativnih trudnica.
English: No effect (↔) equals a decrease in mean ratio estimate of ≤ 20% or increase in mean ratio estimate of (CYP3A4 induction)
Croatian: Bez učinka (↔) odgovara smanjenju procijenjenog omjera srednjih vrijednosti za ≤ 20% ili povećanju procijenjenog omjera srednjih vrijednosti za ≤ 25%. (indukcija CYP3A4)
English: Interaction with didanosine: Co-administration of Atripla and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Croatian: Interakcija s didanozinom: Ne preporučuje se istodobna primjena Atriple i didanozina jer rezultira 40-60%-tnim povećanjem sistemske izloženosti didanozinu što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
English: Atovaquone and proguanil hydrochloride/Emtricitabine
Croatian: atovakvon i progvanil hidroklorid/emtricitabin
English: Dose adjustments of calcium channel blockers when co-administered with Atripla should be guided by clinical response (refer to the Summary of Product Characteristics for the calcium channel blocker).
Croatian: Podešavanja doze blokatora kalcijevih kanala kada se primjenjuju istodobno s Atriplom treba usklađivati s kliničkim odgovorom (pogledajte sažetak opisa svojstava lijeka za blokator kalcijevih kanala).
English: Since efavirenz is principally metabolised by the CYP system, caution should be exercised in administering Atripla to patients with mild hepatic impairment.
Croatian: Budući da se efavirenz primarno metabolizira putem CYP sustava, potreban je oprez pri davanju Atriple bolesnicima s blagim oštećenjem jetre.
English: The adverse reaction profile of efavirenz, emtricitabine and tenofovir disoproxil in patients co-infected with HIV/HBV or HIV/HCV was similar to that observed in patients infected with HIV without co-infection.
Croatian: Profil nuspojava efavirenza, emtricitabina i tenofovirdizoproksila u bolesnika s istodobnom infekcijom HIV/HBV ili HIV/HCV bio je sličan profilu koji je zapažen u bolesnika zaraženih virusom HIV-a bez istodobne druge infekcije.
English: Tenofovir pharmacokinetics were not substantially altered in subjects with hepatic impairment suggesting that no dose adjustment of tenofovir disoproxil is required in these subjects.
Croatian: Farmakokinetika tenofovira nije se bitno izmijenila u ispitanika s oštećenjem funkcije jetre, što navodi na zaključak da u tih ispitanika nije potrebno prilagođavati dozu tenofovirdizoproksila.
English: Most frequent side effects
Croatian: Najčešće nuspojave
English: Barrier contraception should always be used in combination with other methods of contraception (for example, oral or other hormonal contraceptives, see section 4.5) while on therapy with Atripla.
Croatian: Tijekom terapije Atriplom barijerna kontracepcija se uvijek treba koristiti u kombinaciji s drugim metodama kontracepcije (na primjer, oralnim ili drugim hormonalnim kontraceptivima, vidjeti dio 4.5).
English: Co-administration of standard doses of efavirenz and voriconazole is contraindicated (see section 4.3).
Croatian: Istodobna primjena standardnih doza efavirenza i vorikonazola je kontraindicirana (vidjeti dio 4.3).
English: - if you have a history of convulsions (fits or seizures) or if you are being treated with anticonvulsant therapy such as carbamazepine, phenobarbital and phenytoin.
Croatian: ako ste nekada imali konvulzije (napadaje) ili ste liječeni antikonvulzivima kao što su karbamazepin, fenobarbital i fenitoin.
English: Rashes may be caused by Atripla.
Croatian: Atripla može uzrokovati pojavu osipa.
English: Atripla can reduce the amount of the anticonvulsant in your blood.
Croatian: Atripla može smanjiti koncentraciju antikonvulziva u krvi.
English: Patients with renal impairment: Since tenofovir disoproxil can cause renal toxicity, close monitoring of renal function is recommended in any patient with mild renal impairment treated with Atripla (see sections 4.2, 4.4 and 5.2).
Croatian: Bolesnici s oštećenjem funkcije bubrega: Tenofovirdizoproksil može prouzročiti bubrežnu toksičnost pa se preporučuje pomno nadziranje funkcije bubrega u svakog bolesnika s blagim oštećenjem funkcije bubrega koji se liječi Atriplom (vidjeti dio 4.2, 4.4 i 5.2).
English: Atripla is not recommended if you have moderate to severe kidney disease.
Croatian: Uzimanje Atriple ne preporučuje se ako imate umjerenu ili tešku bolest bubrega.
English: Concomitant administration with Atripla should be avoided due to the risk for QTc prolongation (see section
Croatian: Treba izbjegavati istodobnu primjenu s Atriplom zbog rizika od produljenja QTc-a (vidjeti dio 4.3).
English: ↓ exposure of the immunosuppressant may be expected (CYP3A4 induction).
Croatian: Može se očekivati ↓ izloženosti imunosupresivu (indukcija CYP3A4).
English: An alternative anticonvulsant should be considered.
Croatian: Potrebno je razmotriti primjenu drugog antikonvulziva.
English: Close monitoring of immunosuppressant concentrations for at least two weeks (until stable concentrations are reached) is recommended when starting or stopping treatment with Atripla.
Croatian: početka ili prekida terapije Atriplom preporučuje se pomno praćenje koncentracija imunosupresiva tijekom najmanje dva tjedna (dok se ne postignu stabilne koncentracije).
English: • increases in creatinine in the blood
Croatian: • povećanu razinu kreatinina u krvi
English: Atripla must be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement or fever.
Croatian: Primjena Atriple mora se prekinuti ako se u bolesnika razvije težak osip povezan s nastajanjem mjehura, deskvamacija, uključenost sluznica ili povišena tjelesna temperatura.
English: No effect (↔) equals a decrease in mean ratio estimate of ≤ 20% or increase in mean ratio estimate of
Croatian: Bez učinka (↔) odgovara smanjenju procijenjenog omjera srednjih vrijednosti za ≤ 20% ili povećanju procijenjenog omjera srednjih vrijednosti za ≤ 25%.
English: Your doctor may do blood tests to see if your kidneys are working properly
Croatian: Liječnik će Vam možda napraviti krvne pretrage da provjeri rade li bubrezi ispravno.
English: Your doctor may need to consider changing your dose or giving you an alternative antibiotic.
Croatian: Liječnik će možda morati razmotriti mijenjanje doze ili uvođenje drugog antibiotika.
English: Atripla must not be administered concurrently with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, or ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine), since inhibition of their metabolism may lead to serious, life-threatening events (see section 4.3).
Croatian: Atripla se ne smije uzimati istodobno s terfenadinom, astemizolom, cisapridom, midazolamom, triazolamom, pimozidom, bepridilom ili ergot alkaloidima (na primjer, ergotamin, dihidroergotamin, ergonovin i metilergonovin) jer inhibicija njihovih metabolizama može dovesti to ozbiljnih i po život opasnih učinaka (vidjeti dio 4.3).
English: Due to similarities with emtricitabine, Atripla should not be administered concomitantly with other cytidine analogues, such as lamivudine.
Croatian: Zbog sličnosti s emtricitabinom, Atripla se ne smije primjenjivati istodobno s drugim analozima citidina, kao što je lamivudin.
English: * p-value < 0.05, Fisher's Exact test comparing efavirenz + emtricitabine + tenofovir disoproxil group to efavirenz
Croatian: * p-vrijednost < 0,05, Fisherov egzaktni test koji uspoređuje skupinu efavirenz + emtricitabin + tenofovirdizoproksil sa skupinom efavirenz + lamivudin/zidovudin među svim bolesnicima.
English: In repeated-dose toxicity studies, biliary hyperplasia was observed in cynomolgus monkeys given efavirenz for ≥ 1 year at a dose resulting in mean AUC values approximately 2-fold greater than those in humans given the recommended dose.
Croatian: Bilijarna hiperplazija uočena je u ispitivanjima toksičnosti ponovljenih doza provedenima na majmunima vrste cynomolgus kojima je ≥ 1 godine davan efavirenz u dozama uz koje je postignuta približno 2 puta viša srednja vrijednost AUC nego kod ljudi koji su primali preporučenu dozu.
English: A reliable method of barrier contraception must be used in addition to hormonal contraceptives (see section 4.6).
Croatian: Osim hormonskih kontraceptiva mora se koristiti i pouzdana metoda barijerne kontracepcije (vidjeti dio 4.6).
English: Co-administration of tenofovir disoproxil and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
Croatian: Istodobna primjena tenofovirdizoproksila i didanozina dovodi do povećanja sistemske izloženosti didanozinu od 40-60%, što može povećati rizik od nuspojava povezanih s didanozinom.
English: In 35 patients receiving efavirenz 600 mg once daily, steady-state peak concentration (Cmax) was 12.9 ± 3.7 µM (29%) [mean ± standard deviation (S.D.) (coefficient of variation (%CV))], steady-state Cmin was 5.6 ± 3.2 µM (57%), and AUC was 184 ± 73 µM•h (40%).
Croatian: U 35 bolesnika koji su primali 600 mg efavirenza jednom dnevno, vršna vrijednost koncentracije (Cmax) u stanju dinamičke ravnoteže bila je 12,9 ± 3,7 µM (29%) [srednja vrijednost ± standardna devijacija (SD) (koeficijent varijacije (%CV))], Cmin u stanju dinamičke ravnoteže 5,6 ± 3,2 µM (57%) i AUC 184 ± 73 µM•h (40%).
English: Tenofovir disoproxil (n=45)
Croatian: tenofovirdizoproksil (n=45)
English: Pharmacokinetic parameters were determined following administration of single doses of the individual preparations of emtricitabine 200 mg or tenofovir disoproxil 245 mg to non-HIV infected patients with varying degrees of renal impairment.
Croatian: Farmakokinetički parametri određeni su uglavnom nakon primjene jednokratnih doza pojedinačnih formulacija od 200 mg emtricitabina ili 245 mg tenofovirdizoproksila kod bolesnika koji nisu bili inficirani virusom HIV-a, a imali su različiti stupanj oštećenja funkcije bubrega.
English: Uncommon rhabdomyolysis2, muscular weakness2
Croatian: Manje često rabdomioliza2, mišićna slabost2
English: In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
Croatian: U bolesnika s uznapredovalom bolesti jetre ili cirozom jetre ne preporučuje se prekid liječenja, jer egzacerbacija hepatitisa nakon liječenja može dovesti do dekompenzacije jetre.
English: Caution must be taken in any patient with a history of seizures.
Croatian: Oprez je potreban kod svih bolesnika s napadajima u anamnezi.
English: Atripla is not recommended for patients who have had a life-threatening cutaneous reaction (e.g., Stevens-Johnson syndrome) while taking an NNRTI.
Croatian: Uzimanje Atriple ne preporučuje se bolesnicima u kojih se tijekom uzimanja NNRTI lijekova pojavila po život opasna kožna reakcija (npr. Stevens-Johnsonov sindrom).
English: Rare events of renal impairment, renal failure and uncommon events of proximal renal tubulopathy (including Fanconi syndrome) sometimes leading to bone abnormalities (infrequently contributing to fractures) have also been reported.
Croatian: Zabilježeni su i su rijetki slučajevi oštećenja bubrega, zatajenja bubrega i manje česti slučajevi proksimalne bubrežne tubulopatije (uključujući Fanconijev sindrom), što je ponekad dovelo do abnormalnosti kostiju (rijetko pridonoseći nastanku prijeloma).
English: Atripla must not be used in patients with severe hepatic impairment (see section 4.3) and is not recommended for patients with moderate hepatic impairment.
Croatian: Atripla se ne smije davati bolesnicima s teškim oštećenjem funkcije jetre (vidjeti dio 4.3) i ne preporučuje se bolesnicima s umjerenim oštećenjem funkcije jetre.
English: In patients with a history of renal dysfunction or in patients who are at risk of renal dysfunction, a more frequent monitoring of renal function is required.
Croatian: U bolesnika s anamnezom bubrežne disfunkcije ili rizikom od poremećaja funkcije bubrega potrebno je češće pratiti funkciju bubrega.
English: - Independent of a history of liver disease, your doctor will consider regular blood tests to check how your liver is working.
Croatian: Bez obzira jeste li ili niste do sada imali bolesti jetre, liječnik će razmotriti potrebu za redovitim krvnim pretragama da bi se utvrdilo kako Vaša jetra radi.
English: If you notice any symptoms of infection, please tell your doctor at once.
Croatian: Ako opazite bilo koji od simptoma infekcije, odmah o tome obavijestite liječnika.
English: If you do miss a dose of Atripla within 12 hours of when it is usually taken, take it as soon as you can, and then take your next dose at its regular time.
Croatian: Ako ipak propustite uzeti jednu dozu Atriple, a to ste primijetili prije nego je proteklo 12 sati od vremena kada Atriplu obično uzimate, uzmite dozu čim možete, a potom sljedeću dozu uzmite u redovito vrijeme.
English: Atripla is contraindicated in patients with severe hepatic impairment (see section 4.3) and not recommended in patients with moderate hepatic impairment.
Croatian: Atripla je kontraindicirana u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.3) i ne preporučuje se bolesnicima s umjerenim oštećenjem funkcije jetre.
English: Since Atripla is a fixed-dose combination product, the dose of efavirenz cannot be altered (see section 4.5).
Croatian: Budući da je Atripla kombinirani lijek s fiksnim dozama, doza efavirenza ne može se mijenjati (vidjeti dio 4.5).
English: If the patient vomits more than 1 hour after taking Atripla he/she does not need to take another dose.
Croatian: Ako bolesnik povraća nakon više od 1 sata od uzimanja Atriple, nije potrebno uzeti još jednu dozu.
English: Gastrointestinal disorders: Very common diarrhoea, nausea diarrhoea, vomiting, nausea
Croatian: Poremećaji probavnog sustava: Vrlo često proljev, mučnina proljev, povraćanje, mučnina
English: Stevens-Johnson syndrome, erythema multiforme3, severe rash angioedema4
Croatian: Stevens-Johnsonov sindrom, multiformni eritem3, težak osip (< 1%)
English: Co-administration of ritonavir at doses of 600 mg and Atripla is not recommended.
Croatian: Ne preporučuje se istodobna primjena ritonavira u dozama od 600 mg s Atriplom.
English: Co-administration of Atripla with elbasvir/grazoprevir is contraindicated because it may lead to loss of virologic response to elbasvir/grazoprevir.
Croatian: Istodobna primjena Atriple i elbasvira/grazoprevira kontraindicirana je jer može dovesti do gubitka virološkog odgovora na elbasvir/grazoprevir.
English: Discontinuation of Atripla therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
Croatian: Prekid liječenja Atriplom u bolesnika istodobno inficiranih HIV-om i HBV-om može biti povezan s teškim akutnim egzacerbacijama hepatitisa.
English: A multiple-dose study of efavirenz showed no significant effect on efavirenz pharmacokinetics in patients with mild hepatic impairment (Child-Pugh-Turcotte Class A) compared with controls.
Croatian: U ispitivanju efavirenza s primjenom višestrukih doza nisu utvrđeni značajni učinci na farmakokinetiku efavirenza u bolesnika s blagim oštećenjem jetre (stadij A Child-Pugh-Turcotte) u usporedbi s kontrolnom skupinom.
English: If a patient is already taking St. John's wort, stop St. John's wort, check viral levels and if possible efavirenz levels.
Croatian: Ako bolesnik već uzima gospinu travu, treba prestati s njezinim uzimanjem te se moraju provjeriti razine virusa i, ako je moguće, razine efavirenza.
English: A similar reduction in indinavir exposures was observed when indinavir 1,000 mg q8h was given with efavirenz 600 mg q.d.
Croatian: Slično smanjenje izloženosti indinaviru uočeno je kada je indinavir u dozi 1000 mg q8h davan zajedno s efavirenzom u dozi 600 mg q.d. (indukcija CYP3A4)
English: The separate pharmaceutical forms of efavirenz, emtricitabine and tenofovir disoproxil were used to determine the pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil, administered separately in HIV infected patients.
Croatian: Zasebni farmaceutski oblici efavirenza, emtricitabina i tenofovirdizoproksila korišteni su da bi se utvrdila farmakokinetika efavirenza, emtricitabina i tenofovirdizoproksila koji su zasebno davani bolesnicima inficiranima virusom HIV-a.
English: If you are taking any of these medicines, tell your doctor immediately.
Croatian: Uzimate li bilo koji od tih lijekova, bez odlaganja to recite svojem liječniku.
English: • allergic reaction (hypersensitivity) that may cause severe skin reactions (Stevens-Johnson syndrome, erythema multiforme, see section 2)
Croatian: • alergijska reakcija (preosjetljivost) koja može uzrokovati teške reakcije na koži (Stevens
English: No malformations were observed in foetuses from efavirenz-treated rats and rabbits.
Croatian: Nisu uočene malformacije zametaka u štakora i kunića koji su primali efavirenz.
English: Atripla should not be administered concomitantly with adefovir dipivoxil or with medicinal products containing tenofovir alafenamide.
Croatian: Atripla se ne smije primjenjivati istodobno s adefovirdipivoksilom ili s lijekovima koji sadrže tenofoviralafenamid.
English: Elbasvir/grazoprevir: Co-administration of Atripla with elbasvir/grazoprevir is contraindicated because it may lead to loss of virologic response to elbasvir/grazoprevir (see section 4.3 and Table 1).
Croatian: Elbasvir/grazoprevir: Istodobna primjena Atriple i elbasvira/grazoprevira kontraindicirana je jer može dovesti do gubitka virološkog odgovora na elbasvir/grazoprevir (vidjeti dio 4.3 i tablicu 1).